Biotechnology

Vazyme

Vazyme released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 320.65 M, actual EPS CNY 0.01

Vazyme to Release FY2026 Q1 Earnings on April 23 After-Market (BJT)

Vazyme to Release FY2025 Earnings on April 23 Pre-Market (BJT), Forecast Revenue CNY 1.468 B, EPS CNY 0.1333

Vazyme released FY2025 Q4 earnings on February 26 Pre-Market (BJT), actual revenue CNY 425.48 M, actual EPS CNY -0.0347

Vazyme released FY2025 Annual Earnings on February 26 Pre-Market (BJT), actual revenue CNY 1.378 B (forecast CNY 1.468 B), actual EPS CNY -0.04 (forecast CNY 0.1333)

Vazyme released FY2025 Q3 earnings on October 29 After-Market BJT, actual revenue CNY 346.18 M, actual EPS CNY 0.0095

Vazyme released FY2025 9 Months earnings on October 29 After-Market (BJT), actual revenue CNY 952.4 M, actual EPS CNY 0.0195

Vazyme FY2025 Q3 Earnings Release on October 30 After-Market BJT

Vazyme released FY2025 Semi-Annual earnings on August 28 Pre-Market (BJT), actual revenue CNY 606.22 M, actual EPS CNY 0.01

Vazyme released FY2025 Q2 earnings on August 28 Pre-Market BJT, actual revenue CNY 321.24 M, actual EPS CNY 0.005

Vazyme to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Nuovision Plans to Repurchase Shares for 5 to 10 Million Yuan

Norvagen Chairman Proposes Share Repurchase

Nuovision Shares Up, Dongwu Securities Gives Buy Rating

Nanoport Biopharma and Novozyme Sign Synthetic Biology Cooperation Agreement

NovaZyme and Nuotai Bio Sign Synthetic Biology Cooperation Project and Joint Venture

Vazyme released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 284.98 M, actual EPS CNY 0.005

Vazyme FY2025 Q1 Earnings Release Scheduled for April 29, After-Market BJT

Nuo Wei Zan Releases 2024 Annual Report, Revenue of 1.378 Billion Yuan, Net Loss Narrowed

Vazyme to Release FY2024 Annual Earnings on April 10 After-Market BJT, Forecast Revenue 1.482 B CNY, EPS 0.17 CNY

688710

159859

688105

Novo Nordisk announced the main clinical trial results of Reimagine 2. Novo Cagrisema demonstrated a weight loss effect of up to 14.2%. Cagrisema shows better weight loss effects compared to Semaglutide

Wallstreetcn

INNOSTAR

Tianhong CNI BIOMEDICINE ETF

Novo Nordisk AS

Guotai CSI Bio-medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

R&G Pharma

ChinaAMC CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

688768

Three Asian stocks identified as potentially undervalued include Anhui Ronds Science & Technology, trading at CN¥50.81 with a 45.1% discount to its fair value of CN¥92.54; Nanjing Vazyme Biotech, trading at CNY 22.3 with a 32.6% discount to its fair value of CNY 33.06; and Baycurrent, trading at ¥6,828 with a 34.5% discount to its fair value of ¥10,424.18. These companies show promising growth potential despite current market conditions, making them attractive for investors seeking undervalued opportunities.

Simplywall

Ronds

3 Asian Stocks That May Be Trading Below Fair Value By Up To 45.1%

Vazyme's wholly-owned subsidiary, Nanjing Vazyme Medical Technology Co., Ltd., recently obtained multiple medical device registration certificates, involving a series of diagnostic reagent products for the nervous system. The company relies on its antibody technology platform to continuously enrich its AD blood test series products and innovatively develop precise detection products for Parkinson's disease and brain injuries, aiming to meet clinical needs in the field of neurological diseases and enhance the diagnosis and treatment service level for brain health and cognitive disorders

Zhitong

Vazyme's subsidiary products have obtained medical device registration certificates

According to the Zhitong Finance APP, Vazyme announced that due to its own funding needs, the company's shareholder China Life Chengda intends to reduce its holdings of the company's shares by a total of no more than 11.932 million shares, which is no more than 3% of the company's total share capital, within three months after the 15 trading days following the announcement of the reduction plan

Vazyme: China Life Chengda plans to reduce its holdings by no more than 3%

Vazyme has signed an agreement with Yimiao Shenzhou to jointly establish a biopharmaceutical joint venture with a registered capital of 40 million yuan, with both parties holding 50% of the shares. The joint venture will focus on the field of cell therapy, dedicated to the screening, prevention, and treatment of Alzheimer's disease. This investment does not require review by the board of directors or shareholders' meeting and is expected to have no significant impact on the performance for the year 2025

Vazyme: Plans to establish a joint venture with Yimiao Shenzhou, holding 50% of the shares

688076

According to the Qichacha APP, recently, Nanjing Sinopep Biopharmaceutical Co., Ltd. was established with a registered capital of 20 million yuan. The business scope includes: research and development of bio-based material technology; research and development of industrial enzyme preparations; research and development of biological feed; research and development of biochemical products technology, etc. Qichacha's equity penetration shows that the company is jointly held by Sinopep and Vazyme

Sinopep

ST Sinopep, Vazyme and others establish a new biopharmaceutical company

According to the Zhitong Finance APP, Vazyme announced that the company plans to repurchase part of its issued ordinary shares (A shares) through centralized bidding. The amount for the repurchase is between RMB 5 million (inclusive) and RMB 10 million (inclusive), with the repurchase price not exceeding RMB 30 per share (inclusive). The repurchase period is within 12 months from the date the board of directors approves this repurchase plan

Vazyme plans to repurchase company shares for 5 million to 10 million yuan

Vazyme Chairman and General Manager Cao Lin proposed that the company repurchase a portion of its shares, with an amount between 5 million and 10 million yuan, at a repurchase price not exceeding 30 yuan per share, within a period of 12 months. This move aims to be used for the company's equity incentive or employee stock ownership plan

Vazyme's actual controller, Cao Lin, proposed to spend between 5 million to 10 million yuan to implement a share repurchase

Vazyme(688105.SH)